2018-003219-23: CHIEF-PD (CHolinesterase Inhibitor to prEvent Falls in Parkinson’s Disease) |
|
|
| Not yet recruiting | 3 | 600 | Europe | Rivastigmin Luye Transdermal Patches - 4.6mg/24h, Rivastigmine Luye Transdermal Patch- 9.5mg/24h, Rivastigmine transdermal system 13.3 mg/24 h, N/A, RIV-TDS 13.3 mg/24 h, Transdermal patch, Rivastigmin Luye Transdermal Patches - 4.6mg/24h, Rivastigmine Luye Transdermal Patch- 9.5mg/24h | University of Bristol, National Institute for Health Research, Health Assessment Technology Programme | This trial will investigate the effectiveness of Rivastigmine on prevention of falls in patients with Parkinson's disease, Parkinson's Disease is a condition in which the nervous system is damaged which leads to a loss of control of the muscles that control walking and balance., Diseases [C] - Nervous System Diseases [C10] | | | | |
| Active, not recruiting | 3 | 600 | Europe | Rivastigmine Transdermal System, Placebo Transdermal System | University of Bristol, Royal United Hospitals Bath NHS Foundation Trust | Parkinson Disease | 05/24 | 02/25 | | |
